河南农业科学 ›› 2022, Vol. 51 ›› Issue (6): 134-143.DOI: 10.15933/j.cnki.1004-3268.2022.06.015

所属专题: 动物新型疫苗专题

• 畜牧·兽医 • 上一篇    下一篇

2020—2021 年市售马立克病疫苗的效价测定及质量评估

郑鹿平1,2,滕蔓1,2,刘金玲1,2,罗琴1,2,3,楚钰淑1,2,王伟东1,2,4,张文凯1,2,5,罗俊1,2,5
  

  1. (1.河南省农业科学院动物免疫学重点实验室/农业农村部动物免疫学重点实验室/河南省动物免疫学重点实验室,河南 郑州 450002;2.河南省农业科学院中英禽病国际研究中心,河南 郑州 450002;3.河南牧业经济学院动物医药学院,河南 郑州 450046;4.郑州大学公共卫生学院,河南 郑州 450001;5.河南科技大学动物科技学院,河南 洛阳 471003)
  • 收稿日期:2021-12-15 出版日期:2022-06-15 发布日期:2022-08-17
  • 通讯作者: 罗俊(1978-),男,河南罗山人,研究员,博士,主要从事动物病毒学研究。E-mail:luojun593@aliyun.com
  • 作者简介:郑鹿平(1984-),女,河南扶沟人,助理研究员,硕士,主要从事家禽免疫抑制病与肿瘤病研究。E-mail:1064033209@qq.com
  • 基金资助:
    国家自然科学基金项目(U21A20260);河南省重点研发与推广专项(212102110097);河南省自然科学基金(212300410359);河南省农业科学院自主创新项目(2022ZC65)

Virus Titer Determination and Quality Evaluation of the Commercial Marek’s Disease Vaccines Sold in 2020—2021

ZHENG Luping1,2,TENG Man1,2,LIU Jinling1,2,LUO Qin1,2,3,CHU Yushu1,2,WANG Weidong1,2,4,ZHANG Wenkai1,2,5,LUO Jun1,2,5   

  1. (1.Key Laboratory of Animal Immunology,Henan Academy of Agricultural Sciences/Ministry of Agriculture and Rural Affairs of China & Henan Provincial Key Laboratory of Animal Immunology,Zhengzhou 450002,China;2.UK⁃China Centre of Excellence for Research on Avian Diseases,Henan Academy of Agricultural Sciences,Zhengzhou 450002,China;3.College of Veterinary Medicine,Henan University of Animal Husbandry and Economy,Zhengzhou 450046,China;4.College of Public Health,Zhengzhou University,Zhengzhou 450001,China;5.College of Animal Science and Technology,Henan University of Science and Technology,Luoyang 471003,China)
  • Received:2021-12-15 Published:2022-06-15 Online:2022-08-17

摘要: 为了解和评估现有鸡马立克病(MD)疫苗的质量,采用间接免疫荧光试验(IFA)对2020—2021年市场销售的9家不同企业生产的11个批次MD疫苗产品进行病毒效价测定和对比分析,同时用ELISA试剂盒、胶体金试纸条或RT-PCR 方法分别对禽白血病病毒(ALV)和禽网状内皮组织增生症病毒(REV)的污染状况进行检测。结果表明,在所检测的MD液氮苗中,3批进口或国产的CVI988单价液氮苗之间病毒效价无显著差异,2批不同品牌814单价液氮苗效价差异显著(P<0.05),2批不同品牌双价液氮苗(CVI988+HVT或814+HVT)病毒效价差异极显著(P<0.01),但上述全部类型液氮苗产品的病毒效价均大于5 500 PFU/羽份,达到国标规定值2倍以上。然而,4批不同品牌HVT冻干苗的病毒效价均远低于产品说明书标注的2 000 PFU/羽份,仅为83.90~109.50 PFU/羽份。全部MD 疫苗产品的ALV和REV检测结果均为阴性,表明这些产品洁净无污染。

关键词: 马立克病, 疫苗, 效价测定, 间接免疫荧光试验, 禽白血病病毒, 禽网状内皮组织增生症病毒

Abstract: The effective prevention and control of Marek’s disease(MD)mainly depends on vaccine immunization. In order to determine and evaluate the quality of present MD vaccines,virus titers of 11 commercial MD vaccine products provided by 9 distinct companies during 2020—2021 were determined and analyzed by indirect immunofluorescence assay(IFA).Then the potential contamination of avian leukosis virus(ALV)and reticuloendotheliosis virus(REV)was detected using commercial ELISA kits,colloidal gold test strip or RT⁃PCR.The results showed that for all the tested liquid nitrogen vaccines,no significant difference was observed among the three batches of imported or domestic CVI988 vaccines,while significant differences between the two 814 vaccines(P<0.05) and two bivalent MD vaccines(CVI988+HVT or 814+HVT)(P<0. 01)were found. The virus titers of the tested liquid nitrogen MD vaccine products were all above 5 500 PFU/bird,which were more than two folds of value specified in the national standard.However,the virus titers of four freeze⁃dried HVT vaccine products were only about 83.90—109.50 PFU/bird,much lower than 2 000 PFU/bird as indicated in product introductions.Contamination of ALV or REV was not detected in any of the tested MD vaccines,indicating that these vaccines were clean.

Key words: Marek’s disease, Vaccine, Titration, IFA, ALV, REV

中图分类号: